Thilo Schroeder, Ph.D.

Thilo Schroeder, Ph.D. is member of Silverback Therapeutics’ board of directors. He is a Partner at Nextech Invest Ltd., a global venture fund focused on investing in leading oncology companies. Prior to joining Nextech Invest in 2012, Dr. Schroeder worked in research specializing on the development of Designed Ankyrin Repeat Proteins (DARPins) as specific protein inhibitors (licensed to Molecular Partners / SWX:MOLN). He acquired expertise in molecular biology as an Intern at Micromet Ltd. (now Amgen) and during his studies at the University of Sydney. Dr. Schroeder currently serves as board member of Revolution Medicines, IDEAYA Bioscience, Circle Pharma and board observer of Black Diamond Therapeutics. He is a prior board member of Blueprint Medicines (NASDAQ:BPMC) and Peloton Therapeutics (acquired by Merck). He holds a Ph.D. in biochemistry from the University of Zurich in Switzerland, a M.Sc. in biotechnology from the Ecole de Supérieure de Biotechnologie de Strasbourg in France, and a B.Sc. in biology from the Technical University of Darmstadt in Germany.

© Copyright 2020 - Silverback Therapeutics™